Tekla Life Sciences Investors vs Berkshire Hathaway Inc
A head-to-head of Tekla Life Sciences Investors (HQL) and Berkshire Hathaway Inc (BRK-A) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | HQL | BRK-A |
|---|---|---|
| Market Cap | $553.12M | $1.03T |
| P/E (TTM) | 3.07 | 15.41 |
| Forward P/E | 0.00 | 21.10 |
| P/S | 285.35 | 2.78 |
| P/B | 1.02 | 1.44 |
| EV/EBITDA | 0.00 | 0.00 |
| Dividend Yield | 10.14% | — |
| Profit Margin | 505.41% | 18.01% |
| Gross Margin | 100.00% | 23.63% |
| Operating Margin | 99.08% | 16.03% |
| Revenue Growth (YoY) | +463.30% | -3.94% |
| FCF Yield | — | 2.43% |
| Debt / Equity | — | 19.38 |
| Current Ratio | 1.74 | 6.75 |
Share:
Compare Tekla Life Sciences Investors with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.